205 related articles for article (PubMed ID: 20836251)
1. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors.
Cuny GD; Robin M; Ulyanova NP; Patnaik D; Pique V; Casano G; Liu JF; Lin X; Xian J; Glicksman MA; Stein RL; Higgins JM
Bioorg Med Chem Lett; 2010 Jun; 20(12):3491-4. PubMed ID: 20836251
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
Cuny GD; Ulyanova NP; Patnaik D; Liu JF; Lin X; Auerbach K; Ray SS; Xian J; Glicksman MA; Stein RL; Higgins JM
Bioorg Med Chem Lett; 2012 Mar; 22(5):2015-9. PubMed ID: 22335895
[TBL] [Abstract][Full Text] [Related]
3. N
Aboelfotouh HG; Abdallah M; Khalifa H; Aboushady Y; Abadi AH; Engel M; Abdel-Halim M
Arch Pharm (Weinheim); 2024 Jun; 357(6):e2400020. PubMed ID: 38478964
[TBL] [Abstract][Full Text] [Related]
4. Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin.
Kestav K; Uri A; Lavogina D
Curr Med Chem; 2017; 24(21):2276-2293. PubMed ID: 28413956
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of Haspin inhibitors: Kinase inhibitory potency and cellular activity.
Zeinyeh W; Esvan YJ; Josselin B; Defois M; Baratte B; Knapp S; Chaikuad A; Anizon F; Giraud F; Ruchaud S; Moreau P
Eur J Med Chem; 2022 Jun; 236():114369. PubMed ID: 35447555
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of 7-azaindole derivatives bearing benzocycloalkanone motifs as protein kinase inhibitors.
Qhobosheane MA; Legoabe LJ; Josselin B; Bach S; Ruchaud S; Petzer JP; Beteck RM
Bioorg Med Chem; 2020 Jun; 28(11):115468. PubMed ID: 32284225
[TBL] [Abstract][Full Text] [Related]
7. Design of new disubstituted imidazo[1,2-
Elie J; Feizbakhsh O; Desban N; Josselin B; Baratte B; Bescond A; Duez J; Fant X; Bach S; Marie D; Place M; Ben Salah S; Chartier A; Berteina-Raboin S; Chaikuad A; Knapp S; Carles F; Bonnet P; Buron F; Routier S; Ruchaud S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1840-1853. PubMed ID: 33040634
[TBL] [Abstract][Full Text] [Related]
8. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
9. 3H-pyrazolo[4,3-f]quinoline haspin kinase inhibitors and anticancer properties.
Opoku-Temeng C; Dayal N; Aflaki Sooreshjani M; Sintim HO
Bioorg Chem; 2018 Aug; 78():418-426. PubMed ID: 29698892
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
[TBL] [Abstract][Full Text] [Related]
11. Bisubstrate inhibitor approach for targeting mitotic kinase Haspin.
Kestav K; Lavogina D; Raidaru G; Chaikuad A; Knapp S; Uri A
Bioconjug Chem; 2015 Feb; 26(2):225-34. PubMed ID: 25595038
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.
Melms JC; Vallabhaneni S; Mills CE; Yapp C; Chen JY; Morelli E; Waszyk P; Kumar S; Deming D; Moret N; Rodriguez S; Subramanian K; Rogava M; Cartwright ANR; Luoma A; Mei S; Brinker TJ; Miller DM; Spektor A; Schadendorf D; Riggi N; Wucherpfennig KW; Sorger PK; Izar B
Cancer Res; 2020 Feb; 80(4):798-810. PubMed ID: 31882401
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 1H-pyrrolo[3,2-g]isoquinolines.
Defois M; Josselin B; Brindeau P; Krämer A; Knapp S; Anizon F; Giraud F; Ruchaud S; Moreau P
Bioorg Med Chem; 2024 Feb; 100():117619. PubMed ID: 38320389
[TBL] [Abstract][Full Text] [Related]
14. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition.
Huang M; Feng X; Su D; Wang G; Wang C; Tang M; Paulucci-Holthauzen A; Hart T; Chen J
Oncogene; 2020 May; 39(21):4312-4322. PubMed ID: 32300176
[TBL] [Abstract][Full Text] [Related]
16. Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.
Yadav RR; Sharma S; Joshi P; Wani A; Vishwakarma RA; Kumar A; Bharate SB
Bioorg Med Chem Lett; 2015 Aug; 25(15):2948-52. PubMed ID: 26048785
[TBL] [Abstract][Full Text] [Related]
17. Coumestrol Epigenetically Suppresses Cancer Cell Proliferation: Coumestrol Is a Natural Haspin Kinase Inhibitor.
Kim JE; Lee SY; Jang M; Choi HK; Kim JH; Chen H; Lim TG; Dong Z; Lee KW
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064398
[TBL] [Abstract][Full Text] [Related]
18. Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay.
Patnaik D; Jun Xian ; Glicksman MA; Cuny GD; Stein RL; Higgins JM
J Biomol Screen; 2008 Dec; 13(10):1025-34. PubMed ID: 18978305
[TBL] [Abstract][Full Text] [Related]
19. Co-crystal structures of the protein kinase haspin with bisubstrate inhibitors.
Lavogina D; Kestav K; Chaikuad A; Heroven C; Knapp S; Uri A
Acta Crystallogr F Struct Biol Commun; 2016 May; 72(Pt 5):339-45. PubMed ID: 27139824
[TBL] [Abstract][Full Text] [Related]
20. Slowly on, Slowly off: Bisubstrate-Analogue Conjugates of 5-Iodotubercidin and Histone H3 Peptide Targeting Protein Kinase Haspin.
Kestav K; Viht K; Konovalov A; Enkvist E; Uri A; Lavogina D
Chembiochem; 2017 Apr; 18(8):790-798. PubMed ID: 28181383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
